Cancer Prevention Pharmaceuticals is developing therapeutics to reduce the risk and reocurrence of cancer and other diseases.

In partnership with Mallinckrodt Plc, CPP is sponsoring the FAP-310 Pivotal Phase 3 Trial of our lead product, CPP-1X/sul, for Familial Adenomatous Polyposis (FAP). CPP-1X/sul has been granted “Fast Track” and “Orphan Drug” designation from FDA. All patients have completed treatment and trial results are expected in the first quarter of 2019.

With the National Cancer Institute (NCI) and SWOG, CPP is co-sponsoring the PACES Phase 3 Trial in colon cancer survivors and is currently recruiting participants.

CPP is also working collaboratively with research institutions and nonprofit groups in support of their clinical trials in neuroblastoma, gastric cancer and early-onset type 1 diabetes.

We were founded by highly respected leaders in preclinical and clinical cancer prevention research. The CPP team has significant experience in drug development, research, and commercialization.

 

CPP's innovative technology addresses polyamine synthesis and inflammation to reduce cancer risk.

These two processes have long been implicated in cancer development but never successfully utilized together to exploit and treat cancer precursors until now.

CPP's Product Pipeline includes pharmaco-prevention therapies to address colon cancers, pediatric cancers and early-onset Type 1 Diabetes.


Mallinckrodt Pharmaceuticals is collaborating with CPP to bring our CPP-1X/sul FAP Treatment to market.

Mallinckrodt signed an exclusive license to commercialize CPP-1X/sul in North America, including a $5M license fee, 50/50 profit sharing, and up to $174M in future development and sales milestone payments.

© 2019 Cancer Prevention Pharmaceuticals, Inc. All Rights Reserved.                  Legal Notice